Molsidomina Wzf (Molsidomine)

Molsidomine, the active ingredient in Molsidomina Wzf, is a nitric oxide donor presented as an oral dosage form for oral use. It is indicated for the treatment of stable angina pectoris and chronic stable angina in adult patients, helping to reduce myocardial oxygen demand.

GNH USA supplies Molsidomina Wzf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. With a focus on regulatory compliance and product integrity, GNH USA ensures timely delivery and support for healthcare providers across multiple regions.

Molsidomine is employed in the management of coronary artery disease‑related angina by improving myocardial oxygen balance.

Stable angina pectoris: reduces frequency and severity of chest pain episodes. Chronic stable angina: enhances exercise tolerance and delays onset of symptoms. Effort‑induced angina: decreases myocardial oxygen demand during physical activity. Ischemic heart disease: contributes to overall reduction of ischemic episodes.

Molsidomine may cause a range of adverse reactions, most of which are related to its vasodilatory action.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and reddening of the skin, especially on the face and neck. - Dizziness: sensation of light‑headedness, particularly when standing quickly.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Syncope: sudden loss of consciousness due to inadequate cerebral perfusion. - Allergic reaction: rash, itching, swelling, or difficulty breathing indicating possible hypersensitivity.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential complications.

Monitor blood pressure: assess baseline and periodic readings to detect hypotension. Avoid use in severe hypotension: contraindicated when systolic pressure is markedly low. Caution in coronary artery disease: evaluate for ischemic risk before prescribing. Assess hepatic function: adjust use if significant liver impairment is present. Avoid concomitant use with other potent vasodilators: increased risk of additive blood‑pressure effects. Store at room temperature: keep in the original container, protect from moisture and light.

Molsidomine can interact with several cardiovascular agents, requiring careful management.

Major Interactions (Avoid): - Sildenafil or other PDE5 inhibitors: combined effect may cause profound hypotension. - Nitrates (e.g., nitroglycerin): additive vasodilation can lead to unsafe blood‑pressure drops.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance antihypertensive effect, requiring blood‑pressure monitoring. - Calcium‑channel blockers: potential for increased hypotensive episodes, adjust dose as needed. - Other antihypertensive agents: monitor for additive blood‑pressure lowering. - Antihypertensive herbal supplements (e.g., garlic, ginkgo): may potentiate vasodilatory response.